These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 9866424

  • 1. [Cytarabine-induced pericarditis].
    Yamada T, Tsurumi H, Hara T, Sawada M, Oyama M, Moriwaki H.
    Rinsho Ketsueki; 1998 Nov; 39(11):1115-20. PubMed ID: 9866424
    [Abstract] [Full Text] [Related]

  • 2. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Tsukaguchi M, Furukawa Y, Shibano M, Kitani T.
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
    [Abstract] [Full Text] [Related]

  • 3. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
    Kuriya S, Murai K, Miyairi Y, Utsugisawa T, Narigasawa Y, Ito T, Shimosegawa K, Ishida Y.
    Cancer; 1996 Aug 01; 78(3):422-6. PubMed ID: 8697386
    [Abstract] [Full Text] [Related]

  • 4. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T, Yasuyama M, Kawauchi K.
    Am J Hematol; 2005 Jun 01; 79(2):136-41. PubMed ID: 15929101
    [Abstract] [Full Text] [Related]

  • 5. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
    Koyama S, Itou S, Shibata A.
    Rinsho Ketsueki; 1990 Nov 01; 31(11):1891-2. PubMed ID: 2287079
    [Abstract] [Full Text] [Related]

  • 6. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N, Tanaka I, Minami N, Shirakawa S.
    Jpn J Clin Oncol; 1987 Jun 01; 17(2):117-21. PubMed ID: 3475489
    [Abstract] [Full Text] [Related]

  • 7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 01; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 8. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
    Tsubaki K, Horiuchi A, Nagai K, Kanamaru A, Kohsaki M, Kitani T, Tagawa S, Masaoka T, Shibata H, Yasunaga K.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 1):996-1003. PubMed ID: 3457553
    [Abstract] [Full Text] [Related]

  • 9. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
    Kumagawa M, Suzuki K, Nagano M, Takamatsu Y, Suzumiya J, Tamura K.
    Rinsho Ketsueki; 2003 Jun 01; 44(6):404-6. PubMed ID: 12884821
    [Abstract] [Full Text] [Related]

  • 10. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G, Tuncer AM, Sayli T, Güler E, Cetin M, Ozbek N, Mufti GJ.
    Hematol Pathol; 1995 Jun 01; 9(3-4):185-93. PubMed ID: 8655463
    [Abstract] [Full Text] [Related]

  • 11. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650
    [Abstract] [Full Text] [Related]

  • 12. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar 15; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 13. [All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
    Maeda N, Satake S, Okada Y, Asahara S, Hasuike N, Tamura M, Takata M, Tasaka K, Okutani T, Maeda Y, Tomofuji Y, Chinzei T, Saigo K.
    Gan To Kagaku Ryoho; 2001 Mar 15; 28(3):407-10. PubMed ID: 11265415
    [Abstract] [Full Text] [Related]

  • 14. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
    Ueda Y, Mori S, Ito T, Maesako Y, Konishi H, Yagiri Y.
    Rinsho Ketsueki; 1998 May 15; 39(5):348-54. PubMed ID: 9637884
    [Abstract] [Full Text] [Related]

  • 15. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL.
    J Exp Clin Cancer Res; 2004 Sep 15; 23(3):447-54. PubMed ID: 15595635
    [Abstract] [Full Text] [Related]

  • 16. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.
    Leuk Res; 2006 Jul 15; 30(7):813-22. PubMed ID: 16478631
    [Abstract] [Full Text] [Related]

  • 17. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
    Arana-Yi C, Block AW, Sait SN, Ford LA, Barcos M, Baer MR.
    Leuk Res; 2008 Jul 15; 32(7):1043-8. PubMed ID: 18093651
    [Abstract] [Full Text] [Related]

  • 18. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E.
    Cancer; 2003 Mar 01; 97(5):1234-41. PubMed ID: 12599230
    [Abstract] [Full Text] [Related]

  • 19. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T.
    Cancer; 2007 Mar 01; 109(5):907-14. PubMed ID: 17285599
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
    Lemez P, Urbánek V.
    Neoplasma; 2005 Mar 01; 52(5):398-401. PubMed ID: 16151584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.